Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGFPC Investigation
About this trial
The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment.
Participants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study.
They will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.
Eligibility criteria
Qualifiers
Patient over 18 years old
Patients alive after more than three years from diagnosis with stage IV or Stage III NSCLC or SCLC, not treated with cytotoxic chemotherapy at the time of inclusion (the patient may be undergoing imunotherapy, targeted therapy or surveillance).
Patients covered by the French National Health Insurance program or with thirdparty-payer health insurance
Disqualifiers
Difficulties for understanding French
Patients undergoing treatment with cytotoxic chemotherapy
Patients under legal guardianship, under curatorship or tutorship
Insufficient cognitive capacity to answer questions
Trial design
Treatments tested in this trial
- Hospital Anxiety and Depression scale (HAD)
- Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13)
- Questionnaire Aix-Marseille-Université (AMU)
Treatment groups
1,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov